Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESET-TRD oral esketamine versus ECT for non-psychotic treatment-resistant depression
NL-OMON56600Phase 3Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of esketamine in treatment-resistant depression (TRD) (2 arms), sponsored by University Medical Center Groningen. Primary endpoints: Phase 1 primary endpoint and Phase 2 primary endpoint. Started Aug 2022; status: recruiting.
02
Drugs
esketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NL-OMON56600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56600.